The DOI matches its Crossref record; 93 of the 93 references it cites were found in a registry or an index.
The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses
Abstract
IMPORTANCE: The strength of association between surrogate end points and survival in oncology is important to understand because surrogate end points are frequently used in oncology clinical trials, supporting US Food and Drug Administration approvals and National Comprehensive Cancer Network guideline recommendations. OBJECTIVE: To identify and evaluate trial-level meta-analyses of randomized clinical trials quantifying the association between a surrogate end point and overall survival in medical oncology. Trial-level correlations test whether treatments that improve the surrogate end point also improve the final end point and are widely considered the strongest evidence to validate a surrogate end point. EVIDENCE REVIEW: Our literature search was built on earlier reported data sets and updated with Google Scholar and MEDLINE searches conducted on December 26, 2014. For MEDLINE, search terms included ("regression" or "correlation") and "surrogate" and "end point [or endpoint]" and ("oncology" or "cancer"). For Google scholar, search terms included ("regression" or "correlation") and "surrogate end point [or endpoint]" and "overall survival" and "trial level." A total of 108 abstracts were retrieved, and 62 articles were read in full in addition to articles identified through prior reviews. FINDINGS: We found 36 articles in which 65 specific correlations between a surrogate end point and survival were identified. Surrogate end points were studied in the neoadjuvant, adjuvant, locally advanced, and metastatic settings. The most common sources for trials included in the 36 articles were systematic reviews of the published literature (10 of 36; 28%), and published literature and meeting abstracts (14 of 36; 39%). Four meta-analyses (11%) used a convenience sample, and only 5 studies (14%) attempted to include unpublished trials by surveying clinical trial registries. Among these 5 studies, only 352 of 684 eligible trials (51.1%) were included in the analyses. More than half of reported correlations (34 of 65; 52%) were of low strength (r ≤ 0.7). Approximately a quarter (16 of 65; 25%) were of medium strength (r > 0.7 to r < 0.85), and 15 of 65 (23%) were highly correlated (r ≥ 0.85) with survival. CONCLUSIONS AND RELEVANCE: Most trial-level validation studies of surrogate end points in oncology find low correlations with survival. All validation studies use only a subset of available trials. The evidence supporting the use of surrogate end points in oncology is limited.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Echt, D. S., Liebson, P. R., Mitchell, L. B., Peters, R. W., Obias-Manno, D., Barker, A. H., Arensberg, D., Baker, A., Friedman, L., Greene, H. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199103213241201 · Cited by 3,253
Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer
Miller, K., Wang, M., Gralow, J., Dickler, M., Cobleigh, M., Perez, E. A., Shenkier, T., Cella, D., & Davidson, N. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072113 · Cited by 3,081
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
Baselga, J., Campone, M., Piccart, M., Burris, H. A., Rugo, H. S., Sahmoud, T., Noguchi, S., Gnant, M., Pritchard, K. I., Lebrun, F., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1109653 · Cited by 2,863
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Raymond, E., Dahan, L., Raoul, J.-L., Bang, Y.-J., Borbath, I., Lombard-Bohas, C., Valle, J., Metrakos, P., Smith, D., Vinik, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003825 · Cited by 2,567
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Surrogate endpoints in clinical trials: Definition and operational criteria
Prentice, R. L. (1989) · Statistics in Medicine · doi:10.1002/sim.4780080407 · Cited by 2,057
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Aupérin, A., Le Péchoux, C., Rolland, E., Curran, W. J., Furuse, K., Fournel, P., Belderbos, J., Clamon, G., Ulutin, H. C., Paulus, R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2543 · Cited by 1,878
Surrogate End Points in Clinical Trials: Are We Being Misled?
Fleming, T. R., & DeMets, D. L. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-7-199610010-00011 · Cited by 1,651
Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias
Dwan, K., Altman, D. G., Arnaiz, J. A., Bloom, J., Chan, A.-W., Cronin, E., Decullier, E., Easterbrook, P. J., Von Elm, E., Gamble, C., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003081 · Cited by 1,546
Dickersin, K. (1992) · JAMA · doi:10.1001/jama.1992.03480030052036 · Cited by 854
Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer: A Meta-analysis
(2010) · JAMA · doi:10.1001/jama.2010.534 · Cited by 794
Sargent, D. J., Wieand, H. S., Haller, D. G., Gray, R., Benedetti, J. K., Buyse, M., Labianca, R., Seitz, J. F., O'Callaghan, C. J., Francini, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.6071 · Cited by 713
Statistical validation of intermediate endpoints for chronic diseases
Freedman, L. S., Graubard, B. I., & Schatzkin, A. (1992) · Statistics in Medicine · doi:10.1002/sim.4780110204 · Cited by 651
Ioannidis, J. P. A. (1998) · JAMA · doi:10.1001/jama.279.4.281 · Cited by 632
The validation of surrogate endpoints in meta-analyses of randomized experiments
Buyse, M., Molenberghs, G., Burzykowski, T., Renard, D., & Geys, H. (2000) · Biostatistics · doi:10.1093/biostatistics/1.1.49 · Cited by 624
NSCLC Meta-Analyses Collaborative Group (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.7162 · Cited by 604
Piccart, M., Hortobagyi, G. N., Campone, M., Pritchard, K. I., Lebrun, F., Ito, Y., Noguchi, S., Perez, A., Rugo, H. S., Deleu, I., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu456 · Cited by 574
The Cardiac Arrhythmia Suppression Trial: Casting Suppression in a Different Light
Pratt, C. M., & Moyé, L. A. (1995) · Circulation · doi:10.1161/01.cir.91.1.245 · Cited by 460
Jefferson, T., Jones, M., Doshi, P., Spencer, E. A., Onakpoya, I., & Heneghan, C. J. (2014) · BMJ · doi:10.1136/bmj.g2545 · Cited by 447
Buyse, M., Thirion, P., Carlson, R. W., Burzykowski, T., Molenberghs, G., & Piedbois, P. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02528-9 · Cited by 427
Jakubowiak, A. J., Dytfeld, D., Griffith, K. A., Lebovic, D., Vesole, D. H., Jagannath, S., Al-Zoubi, A., Anderson, T., Nordgren, B., Detweiler-Short, K., et al. (2012) · Blood · doi:10.1182/blood-2012-04-422683 · Cited by 423
A Decade of Reversal: An Analysis of 146 Contradicted Medical Practices
Prasad, V., Vandross, A., Toomey, C., Cheung, M., Rho, J., Quinn, S., Chacko, S. J., Borkar, D., Gall, V., Selvaraj, S., et al. (2013) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2013.05.012 · Cited by 381
Self-citationProgression-Free Survival Is a Surrogate for Survival in Advanced Colorectal Cancer
Buyse, M., Burzykowski, T., Carroll, K., Michiels, S., Sargent, D. J., Miller, L. L., Elfring, G. L., Pignon, J.-P., & Piedbois, P. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.8836 · Cited by 354
Burzykowski, T., Buyse, M., Piccart-Gebhart, M. J., Sledge, G., Carmichael, J., Lück, H.-J., Mackey, J. R., Nabholtz, J.-M., Paridaens, R., Biganzoli, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8407 · Cited by 348
Rising, K., Bacchetti, P., & Bero, L. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050217 · Cited by 328
Progression-Free Survival: Meaningful or Simply Measurable?
Booth, C. M., & Eisenhauer, E. A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.7571 · Cited by 324
Biomarkers and surrogate end points—the challenge of statistical validation
Buyse, M., Sargent, D. J., Grothey, A., Matheson, A., & de Gramont, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.43 · Cited by 314
Factors Associated With Failure to Publish Large Randomized Trials Presented at an Oncology Meeting
Krzyzanowska, M. K. (2003) · JAMA · doi:10.1001/jama.290.4.495 · Cited by 314
Fojo, T., Mailankody, S., & Lo, A. (2014) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2014.1570 · Cited by 303
Mauguen, A., Le Péchoux, C., Saunders, M. I., Schild, S. E., Turrisi, A. T., Baumann, M., Sause, W. T., Ball, D., Belani, C. P., Bonner, J. A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6677 · Cited by 246
Mauguen, A., Pignon, J.-P., Burdett, S., Domerg, C., Fisher, D., Paulus, R., Mandrekar, S. J., Belani, C. P., Shepherd, F. A., Eisen, T., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70158-x · Cited by 246
Berruti, A., Amoroso, V., Gallo, F., Bertaglia, V., Simoncini, E., Pedersini, R., Ferrari, L., Bottini, A., Bruzzi, P., & Sormani, M. P. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.2836 · Cited by 245
Tang, P. A., Bentzen, S. M., Chen, E. X., & Siu, L. L. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1935 · Cited by 236
Beltran, P. J., Mitchell, P., Moody, G., Chung, Y., Cajulis, E., Belmontes, B., Radinsky, R., & Calzone, F. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4617 · Cited by 235
Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation
Burzykowski, T., & Buyse, M. (2006) · Pharmaceutical Statistics · doi:10.1002/pst.207 · Cited by 200
Burdett, S., Stephens, R. J., Stewart, L. A., Tierney, J. F., Auperin, A., Chevalier, T. L., Pechoux, C. L., Pignon, J., Arriagada, R., Higgins, J. P., et al. (2008) · Ghent University Academic Bibliography (Ghent University) · Cited by 196
Reversals of Established Medical Practices: Evidence to Abandon Ship
Prasad, V., Cifu, A., & Ioannidis, J. P. A. (2012) · JAMA · doi:10.1001/jama.2011.1960 · Cited by 187
Self-citationYudkin, J. S., Lipska, K. J., & Montori, V. M. (2011) · BMJ · doi:10.1136/bmj.d7995 · Cited by 185
Statistical evaluation of biomarkers as surrogate endpoints: a literature review
Weir, C. J., & Walley, R. J. (2006) · Statistics in Medicine · doi:10.1002/sim.2319 · Cited by 175
Johnson, K. R., Ringland, C., Stokes, B. J., Anthony, D. M., Freemantle, N., Irs, A., Hill, S. R., & Ward, R. L. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70800-2 · Cited by 175
Michiels, S., Le Maître, A., Buyse, M., Burzykowski, T., Maillard, E., Bogaerts, J., Vermorken, J. B., Budach, W., Pajak, T. F., Ang, K. K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70023-3 · Cited by 170
Oba, K., Paoletti, X., Alberts, S., Bang, Y.-J., Benedetti, J., Bleiberg, H., Catalano, P., Lordick, F., Michiels, S., Morita, S., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt270 · Cited by 168
Ciani, O., Buyse, M., Garside, R., Pavey, T., Stein, K., Sterne, J. A. C., & Taylor, R. S. (2013) · BMJ · doi:10.1136/bmj.f457 · Cited by 165
Evolution of the Randomized Controlled Trial in Oncology Over Three Decades
Booth, C. M., Cescon, D. W., Wang, L., Tannock, I. F., & Krzyzanowska, M. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.5456 · Cited by 162
Fizazi, K. S., Jones, R. J., Oudard, S. M., Efstathiou, E., Fred Saad, C., de Wit, R., Bono, J. S. D., Cruz, F. M., Fountzilas, G., Ulys, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5119 · Cited by 156
Publication Bias and Research on Passive Smoking: Comparison of Published and Unpublished Studies
Misakian, A. L., & Bero, L. A. (1998) · JAMA · doi:10.1001/jama.280.3.250 · Cited by 126
Bruzzi, P., Mastro, L. D., Sormani, M. P., Bastholt, L., Danova, M., Focan, C., Fountzilas, G., Paul, J., Rosso, R., & Venturini, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.106 · Cited by 123
Surrogate Outcomes in Clinical Trials: A Cautionary Tale
Svensson, S. A., Menkes, D. B., & Lexchin, J. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.3037 · Cited by 119
Amir, E., Šeruga, B., Kwong, R., Tannock, I. F., & Ocaña, A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.028 · Cited by 119
Foster, N. R., Qi, Y., Shi, Q., Krook, J. E., Kugler, J. W., Jett, J. R., Molina, J. R., Schild, S. E., Adjei, A. A., & Mandrekar, S. J. (2010) · Cancer · doi:10.1002/cncr.25526 · Cited by 110
Shi, Q., de Gramont, A., Grothey, A., Zalcberg, J. R., Chibaudel, B., Schmoll, H., Seymour, M., Adams, R., Saltz, L. B., Goldberg, R. M., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.5887 · Cited by 105
Meta-analysis for the evaluation of surrogate endpoints in cancer clinical trials
Shi, Q., & Sargent, D. J. (2009) · International Journal of Clinical Oncology · doi:10.1007/s10147-009-0885-4 · Cited by 94
Paolettí, X., Oba, K., Bang, Y., Bleiberg, H., Boku, N., Bouché, O., Catalano, P. J., Fuse, N., Michiels, S., Moehler, M. H., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt269 · Cited by 90
Progression-free survival as a surrogate endpoint in advanced breast cancer
Miksad, R. A., Zietemann, V., Gothe, R., Schwarzer, R., Conrads‐Frank, A., Schnell‐Inderst, P., Stollenwerk, B., & Siebert, U. (2008) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462308080495 · Cited by 90
Ciani, O., Davis, S., Tappenden, P., Garside, R., Stein, K., Cantrell, A. J., Saad, E. D., Buyse, M. E., & Taylor, R. S. (2014) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462314000300 · Cited by 87
Lassere, M. N., Johnson, K. R., Schiff, M., & Rees, D. M. (2012) · BMC Medical Research Methodology · doi:10.1186/1471-2288-12-27 · Cited by 86
Individual- and trial-level surrogacy in colorectal cancer
Buyse, M. E., Burzykowski, T., Michiels, S., & Carroll, K. (2008) · Statistical Methods in Medical Research · doi:10.1177/0962280207081864 · Cited by 86
Sherrill, B. H., Amonkar, M. M., Wu, Y., Hirst, C., Stein, S., Walker, M. D., & Cuzick, J. M. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604759 · Cited by 73
Flaherty, K. T., Hennig, M., Lee, S. J., Ascierto, P. A., Dummer, R., Eggermont, A. M. M., Hauschild, A., Kefford, R. F., Kirkwood, J. M., Long, G. V., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70007-5 · Cited by 72
Giessen, C. A., Laubender, R. P., Ankerst, D. P., Stintzing, S., Modest, D. P., Mansmann, U., & Heinemann, V. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1515 · Cited by 70
Kay, A., Higgins, J., Day, A. G., Meyer, R. M., & Booth, C. M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr492 · Cited by 69
Hackshaw, A. K., Knight, A., Barrett-Lee, P. J., & Leonard, R. C. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602858 · Cited by 67
Liposomal doxorubicin in combination with bortezomib for relapsed or refractory multiple myeloma.
Ning, Y. M., He, K., Dagher, R. N., et al. (2007) · PubMed · Cited by 64
Wilkerson, J., & Fojo, T. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181bef8cd · Cited by 62
Hotta, K., Fujiwara, Y., Matsuo, K., Kiura, K., Takigawa, N., Tabata, M., & Tanimoto, M. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181989bd2 · Cited by 58
Sidhu, R., Rong, A., & Dahlberg, S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2502 · Cited by 55
Interim futility analysis with intermediate endpoints
Goldman, B. H., LeBlanc, M. L., & Crowley, J. J. (2008) · Clinical Trials · doi:10.1177/1740774507086648 · Cited by 50
Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology
Sherrill, B. H., Kaye, J. A., Sandin, Cappelleri, & Chen (2012) · OncoTargets and Therapy · doi:10.2147/ott.s36683 · Cited by 49
Bevacizumab for Advanced Breast Cancer: All Tied Up With a RIBBON?
Burstein, H. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.2684 · Cited by 48
Laporte, S., Squifflet, P., Baroux, N., Fossella, F. V., Georgoulias, V., Pujol, J.-L., Douillard, J., Kudoh, S., Pignon, J., Quinaux, E., et al. (2013) · BMJ Open · doi:10.1136/bmjopen-2012-001802 · Cited by 48
Use of Meta-Analysis for the Validation of Surrogate Endpoints and Biomarkers in Cancer Trials
Buyse, M. E. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181b9c602 · Cited by 47
The misguided ethics of crossover trials
Prasad, V. K., & Grady, C. (2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2013.12.003 · Cited by 45
Self-citationElston, J., & Taylor, R. S. (2009) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462309090023 · Cited by 43
Lee, L., Wang, L., & Crump, M. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq615 · Cited by 41
Hayashi, H., Okamoto, I., Taguri, M., Morita, S., & Nakagawa, K. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.09.006 · Cited by 40
Ng, R., Pond, G. R., Tang, P. A., MacIntosh, P. W., Siu, L. L., & Chen, E. X. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm486 · Cited by 40
Petrelli, F., & Barni, S. (2013) · Medical Oncology · doi:10.1007/s12032-013-0776-4 · Cited by 32
Chirila, C., Odom, D. M., Devercelli, G., Khan, S., Sherif, B. N., Kaye, J. A., Molnár, I., & Sherrill, B. H. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1349-7 · Cited by 29
Exploring and validating surrogate endpoints in colorectal cancer
Burzykowski, T., Buyse, M. E., Yothers, G., Sakamoto, J., & Sargent, D. J. (2008) · Lifetime Data Analysis · doi:10.1007/s10985-007-9079-4 · Cited by 28
Progression-free survival as a potential surrogate for overall survival in metastatic breast cancer
Beauchemin, C., Cooper, D., Yelle, L., Lachaîne, J., & Lapierre, M.-È. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s63302 · Cited by 25
Johnson, K. R., Liauw, W., & Lassere, M. N. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu267 · Cited by 24
Lakdawalla, D., Chou, J. W., Linthicum, M. T., MacEwan, J. P., Zhang, J., & Goldman, D. P. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0203 · Cited by 23
Redman, M. W., Goldman, B. H., LeBlanc, M. L., Schott, A. F., & Baker, L. H. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2939 · Cited by 23
Korde, N., Zingone, A., Kwok, M., Manasanch, E. E., Costello, R., Zuchlinski, D., Mulquin, M., Marić, I., Calvo, K. R., Braylan, R. C., et al. (2012) · Blood · doi:10.1182/blood.v120.21.732.732 · Cited by 21
Giessen, C. A., Laubender, R. P., Ankerst, D. P., Stintzing, S., Modest, D. P., Schulz, C. U., Mansmann, U., & Heinemann, V. (2014) · Acta Oncologica · doi:10.3109/0284186x.2014.938830 · Cited by 18
ALTITUDE Trial and Dual RAS Blockade: The Alluring but Soft Science of the Surrogate End Point
Messerli, F. H., & Bangalore, S. (2013) · The American Journal of Medicine · doi:10.1016/j.amjmed.2012.07.006 · Cited by 14
Cardiovascular Primary Prevention
Vandross, A. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.812 · Cited by 12
Self-citation
Cited by
Levey, A. S., Gansevoort, R. T., Coresh, J., Inker, L. A., Heerspink, H. L., Grams, M. E., Greene, T., Tighiouart, H., Matsushita, K., Ballew, S. H., et al. (2020) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.06.009 · Cited by 591
Davis, C., Naci, H., Gurpinar, E., Poplavska, E., Pinto, A., & Aggarwal, A. (2017) · BMJ · doi:10.1136/bmj.j4530 · Cited by 599
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference
Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413
Heerspink, H. J. L., Greene, T., Tighiouart, H., Gansevoort, R. T., Coresh, J., Simon, A. L., Chan, T. M., Hou, F. F., Lewis, J. B., Locatelli, F., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30314-0 · Cited by 397
A Structured Review of the Validity of BLEU
Reiter, E. (2018) · Computational Linguistics · doi:10.1162/coli_a_00322 · Cited by 386
Metadata
- Authors
- Prasad, V., Kim, C., Burotto, M., & Vandross, A.
- Venue
- JAMA Internal Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 2015-08-01
- Volume
- 175
- Issue
- 8
- Pages
- 1389
- ISSN
- 2168-6106 (ISSN-L)
- OpenAlex
- W1570249624
- Cited by
- 403
- References
- 93
- FWCI
- 29.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.